MarketPulse

OCS-01

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Oculis Holding Ag

Oculis Eyes DME Market With First Eye Drop Therapy as ARVO Data Show Unmet Need

Oculis' DME AWARE study confirms expert demand for non-invasive treatment; OCS-01 eye drops target June 2026 Phase 3 results as potential first-in-class DME therapy.
OCSOCSAWdiabetic macular edemanon-invasive treatment
GlobeNewswire Inc.GlobeNewswire Inc.··Oculis Holding Ag

Oculis Eyes DME Market Opportunity as Study Reveals 60% Patient Non-Treatment Rate

Oculis-backed research reveals significant unmet needs in diabetic macular edema treatment, with 60% of patients remaining untreated due to invasive therapies.
OCSOCSAWdiabetic macular edemanon-invasive treatment
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Oculis to Showcase Late-Stage Pipeline at ARVO 2026 as OCS-01 Phase 3 Data Nears

Oculis to present advancing ophthalmology pipeline at ARVO 2026, with Phase 3 OCS-01 DME results expected June 2026.
OCSOCSAWPhase 3 clinical trialdiabetic macular edema
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Oculis Names Veterans Legal Executive as CLO Amid Clinical Pipeline Expansion

Oculis appoints seasoned legal executive Katie Kazem as Chief Legal Officer to strengthen governance as it advances clinical pipeline with late-stage therapeutic candidates.
OCSOCSAWsecurities lawclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Oculis Names Experienced Life Sciences Attorney as Chief Legal Officer

Oculis appoints Katie Kazem as Chief Legal Officer. She brings 15+ years of life sciences legal expertise to support the company's three late-stage clinical programs.
OCSOCSAWsecurities lawclinical trials